MDM2 Inhibitor AMG-232, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions:   Hypercalcemia;   Plasmacytoma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma Interventions:   Drug: Carfilzomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: MDM2 Inhibitor AMG-232;   Other: Pharmacological Study Sponsor:   National Cancer Institute (NCI) Not yet recruiting - verified February 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2017 Category: Research Source Type: clinical trials

MDM2 Inhibitor AMG-232, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions:   Hypercalcemia;   Plasmacytoma;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma Interventions:   Drug: Carfilzomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: MDM2 Inhibitor AMG-232;   Other: Pharmacological Study Sponsor:   National Cancer Institute (NCI) Not yet recruiting - verified January 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 25, 2017 Category: Research Source Type: clinical trials